💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ondansetron

CHEMBL46 Phase 4 承認済み Small molecule
Half-Life
3-5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
293.4 g/mol
LogP
2.3
Phase
4

A selective 5-HT3 receptor antagonist, ondansetron blocks the serotonin signaling that triggers nausea and vomiting. It is used to prevent these symptoms after chemotherapy, radiation, and surgery. With the molecular formula C18H19N3O, it was among the first agents of its class and transformed the tolerability of cancer treatment by controlling emesis that older antiemetics could not.

A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.

分子量

293.3660 g/mol

LogP

2.30

TPSA

39.80 Ų

リピンスキーの五則

適合

治療領域

Oncology Gastroenterology

薬物分類

A — A - Alimentary Tract and Metabolism

作用機序

Selective 5-HT3 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 3-5 hours

Pharmacodynamics (PD)

機序

Selective 5-HT3 receptor antagonist.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19N3O

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Escitalopram
                            
                        

                        
                        
Escitalopram and ondansetron together carry dual risks: serotonin syndrome and additive QT interval prolongation, making this combination particularly dangerous.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Azithromycin
                            
                        

                        
                        
Azithromycin and ondansetron both prolong the cardiac QT interval; their combination substantially increases the risk of torsades de pointes.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits the metabolism of ondansetron and both drugs prolong the QT interval, creating a compounded arrhythmia risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Ciprofloxacin
                            
                        

                        
                        
Ciprofloxacin and ondansetron both prolong the QT interval; combined use raises the risk of torsades de pointes and sudden cardiac death.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ondansetron + Hydroxychloroquine
                            
                        

                        
                        
Hydroxychloroquine and ondansetron both prolong cardiac repolarization via hERG blockade; concurrent use substantially elevates arrhythmia risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective 5-HT3 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Ondansetron: Half-life: 3-5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Ondansetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL46.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4595.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.